The SARS-CoV-2 pandemic interrupted much respiratory research. Respiratory clinical academics joined colleagues in providing clinical care, and global research efforts were directed to finding new ...

Initially developed for atopic dermatitis, Enveda's lead asset ENV-294 is now showing promise in treating asthma.

Targeting IL-4 receptors can address so-called Th2-mediated skin inflammation – a mechanism that the drug shares with Sanofi and Regeneron’s blockbuster AD therapy Dupixent (dupilumab ...

The European Commission has become the first regulator worldwide to approve Sanofi and Regeneron’s IL-4 and IL-13 inhibitor Dupixent (dupilumab ... therapy with a new mechanism of action ...

Fewer than 10% of children or adolescents with peanut allergy passed a desnsitiaztion food challenge after receiving dupilumab for 24 weeks. Image: Adobe Stock “The impact of the findings for ...

A 28-year-old woman developed allergic contact dermatitis within 6 to 24 hours exclusively after using carmine-containing eyeshadows and lipsticks. She had both a positive patch test result and a ...

We report a vesicular reaction close to patch-test sites that had been previously marked with an Edding 3000 permanent marker. A 42-year-old housewife and teacher came to our allergy department ...

The international consulting firm Clarivate makes its bet among the novelties ready for the medicine cabinet this year: three ...

The defects in molecular and cellular processes that constitute the triggers of specific pathologies are referred to as mechanisms of disease. Research in this area is vital for designing ...

And devising ways to sense these compounds could help doctors provide early ... Researchers Identify Key Mechanism in Human Lung Development Oct. 31, 2024 — Researchers have shown that the ...

They collected skin tape strips (STS) from the lesional and non-lesional skin of 20 patients with AD and 20 healthy volunteers (HV) over 16 weeks of dupilumab treatment. STS extracts were analyzed ...

ENV-294: A Transformative Approach to Asthma ENV-294 is a clinical-stage small molecule designed to address the shared pathways underlying multiple inflammatory conditions via a first-in-class ...